Archive

Neovasc to Provide Update on TF/TS Tiara Program at PCR Valves 2019

Posted on November 5, 2019
in
by Andrew Rose

®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Neovasc to Submit Full PMA Application for Neovasc Reducer™ in 2019

Posted on November 1, 2019
in
by Andrew Rose

®NASDAQ, TSX: NVCN VANCOUVER, Nov. 1, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that...

Read More

Neovasc Reducer™ for Treatment of Refractory Angina Featured in Sponsored Session at the 40th Annual National Congress of the Italian Society of Interventional Cardiology

Posted on October 22, 2019
in
by Andrew Rose

®NASDAQ, TSX: NVCN VANCOUVER, Oct. 22, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today...

Read More

Neovasc Retains Westwicke, ICR for Integrated Communications Counsel

Posted on October 16, 2019
in
by Andrew Rose

®NASDAQ, TSX: NVCN VANCOUVER, Oct. 16, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced...

Read More

Neovasc Announces Notice of US Patent Granted for Tiara™ Transcatheter Device for Treatment of Severe Mitral Regurgitation

Posted on October 15, 2019
in
by Andrew Rose

®NASDAQ, TSX: NVCN VANCOUVER, Oct. 15, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced...

Read More

Neovasc and GADA® Sponsor Session at the 40th Annual (GISE) National Congress of the Italian Society of Interventional Cardiology

Posted on October 9, 2019
in
by Andrew Rose

®NASDAQ, TSX: NVCN VANCOUVER and MILAN, Oct. 09, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More